Rosuvastatin acts on the lymphatic system to improve atherosclerosis.
10.3760/cma.j.cn112148-20221128-00937
- Author:
Zi Qi SONG
1
;
Jun Xian SONG
1
;
Yu Xia CUI
1
;
Su Fang LI
1
;
Hong CHEN
1
Author Information
1. Beijing Key Laboratory of Early Warning and Intervention of Acute Myocardial Infarction, Cardiovascular Translational Medicine Research Center, Department of Cardiovascular Medicine, Peking University People's Hospital, Beijing 100044, China.
- Publication Type:Journal Article
- MeSH:
Rats;
Mice;
Animals;
Rosuvastatin Calcium/therapeutic use*;
Vascular Endothelial Growth Factor C;
Endothelial Cells/metabolism*;
Atherosclerosis/drug therapy*;
Plaque, Atherosclerotic;
Cholesterol, HDL;
Lymphatic System/metabolism*
- From:
Chinese Journal of Cardiology
2023;51(3):288-295
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate whether rosuvastatin acts on lymphatic system and influences lymphatic system-mediated reverse cholesterol transport to play an anti-atherosclerosis role. Methods: Forty-eight apolipoprotein E-/- mice fed a high fat diet were used to construct the atherosclerosis model. They were randomly divided into 4 groups with 12 rats in each group. They were treated with rosuvastatin, vascular endothelial growth factor-C (VEGF-C) and rosuvastatin+VEGF-C inhibitors as experimental group, and no intervention measures were given in control group. After 8 weeks, aortic plaque area, high density lipoprotein cholesterol (HDL-C) content in lymph fluid, the function of popliteal lymphatic drainage of peripheral Evans blue, and the ability of lymphatic system to transport peripheral cell membrane red fluorescent probes to label high-density lipoprotein (HDL) were detected. Subsequently, the effects of rosuvastatin on proliferation, migration and tubular function of lymphoendothelial cells and the expression of scavenger receptor class B type 1 (SR-B1) on lymphoendothelial cells at different concentrations were detected. Results: Compared with the control group, Rosuvastatin and VEGF-C could reduce the area of aortic atherosclerotic plaque (P<0.05). In addition to rosuvastatin plus VEGF-C inhibitor, the intra-aortic plaque area increased (P<0.05). Compared with the control group, Rosuvastatin could increase the content of HDL-C in lymphatic fluid (P<0.05), enhance the drainage function of lymphatic vessels, and enhance the capacity of HDL in the transport tissue fluid of lymphatic system. Compared with the control group, VEGF-C increased the content of HDL-C in mouse lymph fluid (P<0.01), enhanced the drainage function of popliteal lymphatic canal, and enhanced the ability of lymphatic system to transport HDL. With the addition of VEGF-C inhibitor on the basis of rosuvastatin, the content of HDL-C in lymph fluid was reduced, the drainage of popliteal lymphatic canal was interrupted, and the ability of lymphatic system to transport HDL was reduced. Western blotting showed that rosuvastatin increased the protein expression of SR-B1. Conclusion: Rosuvastatin can promote the proliferation, migration and tube formation of lymphatic endothelial cells. At the same time, SR-B1 expression on lymphatic endothelial cells is promoted, thus enhancing the lymphatic system mediated cholesterol reversal transport and playing the role of anti-atherosclerosis.
